You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Article metrics

Article menu
XML
Immunotherapy biomarkers
Original research
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: February 2021 to August 2025

AbstractFullPdf
Feb 2021473473162
Mar 2021275275125
Apr 202116316361
May 202118418452
Jun 202117417340
Jul 202115015029
Aug 202112612633
Sep 202111111132
Oct 202110510548
Nov 202110410550
Dec 202111111123
Jan 2022929538
Feb 2022626328
Mar 20229910138
Apr 2022666925
May 2022929730
Jun 202210311031
Jul 2022818222
Aug 2022787937
Sep 2022858629
Oct 2022969823
Nov 2022747628
Dec 2022939315
Jan 2023838330
Feb 202313814025
Mar 2023828338
Apr 2023545526
May 2023515122
Jun 202368688
Jul 2023737319
Aug 202360609
Sep 2023707112
Oct 2023717113
Nov 2023525221
Dec 2023878716
Jan 2024777816
Feb 2024767627
Mar 2024424267
Apr 2024474822
May 2024505125
Jun 2024525324
Jul 2024565722
Aug 2024232414
Sep 2024363630
Oct 2024525223
Nov 2024414225
Dec 2024636518
Jan 2025414122
Feb 202520020017
Mar 2025656528
Apr 202511611645
May 2025626227
Jun 2025383829
Jul 2025110
Aug 2025110
Total502550671719